Research outlook

Where membranous nephropathy treatment is heading

Membranous nephropathy · Updated Nov 14, 2026

Membranous nephropathy is an autoimmune kidney disease and the most common cause of nephrotic syndrome (heavy protein loss in the urine, swelling and high clotting risk) in adults; a few thousand Americans are diagnosed each year. In most cases antibodies against the PLA2R protein on kidney filter cells drive the disease, and a blood test for them can track it. About a third of people improve on their own; others need rituximab, cyclophosphamide with steroids, or calcineurin inhibitors. In 2026 obinutuzumab beat tacrolimus in a phase 3 trial, and several more antibodies are in phase 3.

  1. Now

    Nov 2026

    Obinutuzumab beats tacrolimusHappened 37% complete remission

    Complete remission at 2 years: 37% with obinutuzumab vs 6% with tacrolimus.

    37%: in complete remission at 2 years, vs 6% with tacrolimus.

    Rituximab and cyclophosphamide are comparableHappened 0.85 risk ratio (similar)

    Across 11 studies, remission rates were similar (risk ratio 0.85).

    0.85: risk ratio for remission at 12 months (not significant).

    Targeting plasma cellsHappened 76.9% antibody response

    Felzartamab halved anti-PLA2R antibodies in 76.9%, but one course did not help rituximab-resistant disease.

    76.9%: with at least a 50% drop in anti-PLA2R antibodies.

  2. 6 months

    by May 2027

    Obinutuzumab in guidelinesPossible 37% complete remission

    MAJESTY is likely to shape guidelines and could support an approval application.

    37%: in complete remission at 2 years, vs 6% with tacrolimus.

  3. 12 months

    by Nov 2027

    A BTK inhibitorPossible

    BeOne's ALMOND (178 people) compares zanubrutinib with tacrolimus; due October 2027.

    ACTH gel vs rituximabLong shot

    Cerium's SNP-ACTH trial (148 people) is due April 2027.

  4. 3 years

    by late 2029

    A dual BAFF/APRIL blockerPossible

    Vertex's OLYMPUS (176 people) compares povetacicept with tacrolimus; due December 2028.

  5. 5 years

    by late 2031

    More antibodies head to headPossible 76.9% antibody response (felzartamab)

    Biogen's felzartamab PROMINENT (due January 2030) and Amgen's inebilizumab MOMENT (due September 2031) each compare against tacrolimus.

    76.9%: with at least a 50% drop in anti-PLA2R antibodies.

    Cell therapy for refractory diseaseLong shot

    CAR-NK cells and other cell therapies are in early trials.

Happened Likely Possible Long shot

The research paths

Rising

B-cell antibodies

37% complete remission
Details and 3 trialsHide
Rising

Plasma-cell and BAFF/APRIL targeting

76.9% antibody response
Details and 2 trialsHide
Active

Pills and other approaches

70% antibody clearance
Details and 4 trialsHide

Borrowed from other conditions

From CLL and lupus nephritis

Obinutuzumab

Phase 3

A type II anti-CD20 antibody approved for lymphoma and lupus nephritis.

From Neuromyelitis optica

Inebilizumab

Phase 3

An anti-CD19 antibody approved for NMOSD.

From B-cell lymphomas

Zanubrutinib

Phase 3

A BTK inhibitor approved for several lymphomas.

Open to join now

See every recruiting Membranous nephropathy trial →

When the trials finish

Completion dates the trials registered. Results usually follow 3 to 12 months later.

2026202720282029203020312032Today
SNP-ACTH gel vs rituximabPills and other approaches
Apr 2027
NKX019 CAR-NK cellsPills and other approaches
Apr 2027
ALXN1920Pills and other approaches
Jul 2027
Oct 2027
Zanubrutinib vs tacrolimus (ALMOND)Pills and other approaches
Oct 2027
Povetacicept vs tacrolimus (OLYMPUS)Plasma-cell and BAFF/APRIL targeting
Dec 2028
Belimumab with rituximabB-cell antibodies
Mar 2029
Felzartamab vs tacrolimus (PROMINENT)Plasma-cell and BAFF/APRIL targeting
Jan 2030
Sep 2031

What just happened

Obinutuzumab beats tacrolimus for complete remission

MAJESTY, NEJM.

Felzartamab course fails in rituximab-resistant disease

Kidney Int Rep.

Standard treatment today

How to read this page, and sourcesHow to read this page, and sources

See Membranous nephropathy trials recruiting now →

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.